Clinical Trials

Newly released data from the open-label extension of the FIREFISH study confirmed sustained safety and efficacy of Evrysdi in children with type 1 spinal muscular atrophy over 5 years.

There is a wide capacity for clinical research in India. We have a large, diverse population, large urban hospitals and well-trained specialists. However, for multiple reasons, this capacity is not fully exploited.

I have shared my thoughts on diversity, equity, inclusion and social justice in the U.S. regarding racial distribution in ophthalmology in three prior Lindstrom’s Perspectives.

Due to a complex interplay of genetic, lifestyle and environmental factors, as well as access to health care, the burden for advanced eye disease is highest among racial and ethnic minority groups.

Azura Ophthalmics announced that the first patient has been enrolled in the phase 3 ASTRO study of AZR-MD-001 for patients with clinical signs and symptoms of meibomian gland dysfunction.

SAN DIEGO — Using race-neutral equations to determine eligibility for COPD clinical trials may lead to higher percentages of Black patients enrolled, according to a poster presented at the American Thoracic Society International Conference.

Annexon Biosciences has announced positive topline results from a phase 3, randomized placebo-controlled clinical trial examining an investigational monoclonal antibody in those with Guillain-Barré syndrome.

Takeda has reported positive results from a phase 2b clinical trial of an investigational, oral orexin receptor agonist for narcolepsy type 1.

CHICAGO — More individuals with advanced cancers in the U.S. live within 30 miles of a clinical trial site than a decade ago, but those in rural areas, those with pancreatic disease and American Indians/Alaskan Natives still have access issues.

The European Commission has granted marketing authorization under exceptional circumstances for Qalsody to treat those with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene.